Paul Sekhri

Paul Sekhri is an Executive Partner of Syncona Investment Management Limited.

He brings over 40 years of leadership experience across the global life sciences industry, spanning senior operating roles in multinational pharmaceutical companies, venture-backed biotech firms, and venture capital and private equity organisations.

Paul is currently Chairman, President, and Chief Executive Officer of vTv Therapeutics, Inc. (Nasdaq: VTVT), Independent Chair of Apnimed, Inc. (Nasdaq: APMD), Chair of Resolution Therapeutics and iOnctura Therapeutics, Executive Chairman of Violet Therapeutics and is a director of Veeva Systems (NYSE: VEEV). He was Chair of Longboard Pharmaceuticals until its $2.6 billion acquisition by Lundbeck in 2024. He is an Operating Partner at Petrichor Healthcare Capital Management and an advisor to Epidarex Capital. He has served on more than 40 public, private and non-profit boards throughout his career, 18 of them as Chair.

Previously, Paul was President and CEO of eGenesis, where he led significant advancements in xenotransplantation, and President and CEO of Lycera Corporation. Earlier roles include Senior Vice President, Integrated Care at Sanofi, Chief Strategy Officer and Group Executive Vice President, Global Business Development at Teva Pharmaceutical Industries, and Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, where he oversaw a portfolio of more than 50 life sciences companies. He was also Founder, President and CEO of Cerimon Pharmaceuticals, President and Chief Business Officer of ARIAD Pharmaceuticals, and spent five years at Novartis in global leadership roles including Global Head of Business Development and Licensing.

Syncona portfolio companies

• iOnctura (Chairman)
• Resolution Therapeutics (Chairman)